Immunotherapy Charts New Course for Resectable NSCLC Treatment
Three cycles of neoadjuvant nivolumab plus chemotherapy improved long-term clinical outcomes in patients with resectable stage IB-IIIA NSCLC.
Patrickm Forde Nivolumab Opdivo Bristol Myers Squibb Johns Hopkins Kimmel Cancer Center Drug Administration Medscape Professional Network
Source: medscape.com